• English
    • Türkçe
  • English 
    • English
    • Türkçe
  • Login
View Item 
  •   DSpace Home
  • Araştırma Çıktıları / WOS
  • Araştırma Çıktıları / WOS
  • View Item
  •   DSpace Home
  • Araştırma Çıktıları / WOS
  • Araştırma Çıktıları / WOS
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Design, Synthesis and hMAO Inhibitory Screening of Novel 2-Pyrazoline Analogues

Thumbnail
Date
2017
Author
Evranos-Aksöz, Begüm
Uçar, Gülberk
Yelekçi, Kemal
Abstract
Aim and Objective: MAO inhibitors have a significant effect on the nervous system since they act in regulation of neurotransmitter concentrations. Neurotransmitter levels are critical for a healthy nervous system. MAO inhibitors can be used in the treatment of neurological disorders such as depression, Parkinson's disease and Alzheimer's disease, as the increase or decrease of some neurotransmitter concentrations is associated with these neurological disorders. This study was conducted to discover new and active MAO inhibitor drug candidates. Materials and Methods: New pyrazoline derivatives have been designed with the molecular docking approach and interactions of our compounds with the MAO enzyme have been investigated using the Autodock 4.2 program. The designed pyrazoline derivative compounds were synthesized by the reaction of the chalcones and hydrazides in ethanol. hMAO inhibitory activities of the newly synthesized compounds were investigated by fluorimetric method. In vitro cytotoxicity of five most potent inhibitors were tested in HepG2 cells. Results: (3-(5-bromo-2-hydroxyphenyl)-5-(4-methoxyphenyl)-4,5-dihydropyrazol-1-yl)(phenyl) methanone (5i) and (3-(2-hydroxy-4-methoxy phenyl)-5-p-tolyl-4,5-dihydropyrazol-1-yl)(phenyl) methanone (5l) inhibited hMAO-A more potently than moclobemide (Ki values are 0.004 +/- 0.001 and 0.005 +/- 0.001, respectively). The same two compounds, 5i and 5l, inhibited hMAO-A more selectively than moclobemide (SI values are 5.55x10(-5) and 0.003, respectively). Both of these compounds were found non toxic at 1 mu M, 5 mu M and 25 mu M concentrations. Conclusion: Two of the newly synthesized compounds, (3-(5-bromo-2-hydroxyphenyl)-5-(4-methoxyphenyl)- 4,5-dihydropyrazol-1-yl)(phenyl) methanone and (3-(2-hydroxy-4-methoxy phenyl)5- p-tolyl-4,5-dihydropyrazol-1-yl)(phenyl) methanone were found to be promising MAO-A inhibitors due to their high inhibitory potency, high selectivity and low toxicity.

Source

Combinatorial Chemistry & High Throughput Screening

Issue

6

Volume

20

Pages

510-521

URI

https://doi.org/10.2174/1386207320666170504114208
https://hdl.handle.net/20.500.12469/3686

Collections

  • Araştırma Çıktıları / PubMed [194]
  • Araştırma Çıktıları / Scopus [1565]
  • Araştırma Çıktıları / WOS [1518]
  • Biyoinformatik ve Genetik / Bioinformatics and Genetics [220]

Keywords

2-Pyrazoline
Molecular docking
AutoDock 4.2
Human MAO
Inhibition
Synthesis

Share


DSpace software copyright © 2002-2015  DuraSpace
Contact Us | Send Feedback
Theme by 
@mire NV
 

 

Browse

All of DSpaceCommunities & CollectionsBy Issue DateBy AuthorsBy TitlesBy SubjectsBy TypesBy LanguagesBy DepartmentsBy PublishersBy KHAS AuthorsBy Access TypesThis CollectionBy Issue DateBy AuthorsBy TitlesBy SubjectsBy TypesBy LanguagesBy DepartmentsBy PublishersBy KHAS AuthorsBy Access Types

My Account

LoginRegister

Statistics

View Google Analytics Statistics

DSpace software copyright © 2002-2015  DuraSpace
Contact Us | Send Feedback
Theme by 
@mire NV